ClinicalTrials.gg
CompletedNCT01074047Updated Aug 29, 2017Results posted

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

A Phase 3 interventional study of Azacitidine and Conventional Care Regimen in Acute Myeloid Leukemia, sponsored by Celgene. Completed at 112 sites in 18 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-08-29.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Enrollment
6th of 211
488 · median 50
Started
2010
with 8 others
Phase 3
26 of 214
7 open now
Registered
30th of 214
by date
Lead sponsor
12 of 214
Celgene

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 6th largest by enrollment of the 211 interventional ones that give a count, is one of 9 that started in 2010, is one of 26 in phase 3, and was the 30th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effect of azacitidine (Vidaza) to conventional care regimens on overall survival in elderly AML patients.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • Cytarabine
  • Vidaza
  • azacitidine
  • Intensive Chemotherapy
  • Low Dose Cytarabine
  • Celgene
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of one of the following

    • Newly diagnosed de novo acute myeloid leukemia (AML)
    • AML secondary to myelodysplastic syndromes (MDS)
    • AML secondary to exposure to leukemogenic therapy or agents with primary in remission for at least 2 years
  • Bone marrow blasts >30%
  • Age ≥ 65 years
  • Easter Cooperative Oncology Group () 0-2

Exclusion criteria

Exclusion Criteria:

  • Previous cytotoxic or biologic treatment for AML (except hydroxyurea)
  • Previous treatment with azacitidine, decitabine or cytarabine
  • Prior use of targeted therapy agents (e.g., FLT3 inhibitors, other kinase inhibitors)
  • AML French American British subtype (FAB M3)
  • AML associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes
  • Prior bone marrow or stem cell transplantation
  • Candidate for allogeneic bone marrow or stem cell transplant
  • Diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, "in-situ" carcinoma of the cervix or breast or other local excised or irradiated with a high probability of cure)
  • Malignant hepatic tumors
  • Uncontrolled systemic infection
  • Active viral infection with (HIV) or Hepatitis type B or C
  • Use of any experimental drug or therapy within 28 days prior to Day 1
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
488 participants (actual)

Study arms

  • Experimental
    Azacitidine

    Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity

    Drug: Azacitidine

  • Active comparator
    Conventional Care Regimen

    Conventional Care Regimen

    Drug: Conventional Care Regimen

Interventions

  • 75 mg/m\^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity

    Also known as: Vidaza

  • DrugConventional Care Regimen

    Physician pre-selects prior to randomization from one of the following: * Intensive chemotherapy (cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles * Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity * Best Supportive Care only; until study end

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimates for Overall Survival

    Overall Survival was defined as the time from randomization to death from any cause. Overall survival was calculated by the formula: date of death - date of randomization + 1. Participants surviving at the end of the follow-up period or who withdrew consent to follow-up were censored at the date of last contact. Participants who were lost to follow-up were censored at the date last known alive.

    Time frame: Day 1 (randomization) to 40 months

Secondary outcomes

  1. One-year Overall Survival Rate

    Kaplan Meier methods were used to estimate the 1-year survival probabilities for time to death from any cause. Estimates of the 1-year (365 day) survival probabilities and corresponding 95% confidence intervals (CI) were presented by treatment group. The CI for the difference in the 1-year survival probabilities was derived using Greenwoods variance estimate.

    Time frame: From Day 1 (randomization) to 40 months

  2. Event-free Survival (EFS)

    Event-free survival was defined as the interval from the date of randomization to the date of treatment failure, progressive disease, relapse after complete remission (CR) or complete remission with incomplete blood count recovery (CRi), death from any cause, or lost to follow-up, whichever occurs first. Participants who were still alive without any of these events were censored at the date of their last response assessment.

    Time frame: Day 1 (randomization) to date of treatment failure, progressive disease, relapse after Complete Remission (CR) or Complete remission with incomplete blood count recovery (CRi), death from any cause. Day 1 (randomization) to 40 months

  3. Relapse-Free Survival (RFS) for Participants Who Achieved a Complete Remission (CR) or Complete Remission With Incomplete Blood Count Recovery (CRi)

    Relapse-free survival was defined as the interval from the date of first documented CR or CRi to the date of relapse, death from any cause, or lost to follow-up, whichever occurred first. Participants who were still alive and in continuous CR or CRi were censored at the date of their last response assessment.

    Time frame: Day 1 of first documented CR or CRi to the date of relapse, death from any cause, or lost to follow-up. Day 1 (randomization) to 40 months

  4. Percentage of Participants Who Achieved a Morphologic CR + CRi as Determined by the Independent Review Committee (IRC) Based on International Working Group (IWG) Response Criteria for Acute Myeloid Leukemia (AML)

    A complete remission (CR) is defined as a leukemia-free state defined as less than 5% blasts in a BM aspirate with marrow spicules and with at least 200 nucleated cells (there should be no blasts with Auer rods), an absolute neutrophil count (ANC) of ≥ 1 x 10\^9/L, a platelet count ≥ 100 x 10\^9/L, and transfusion independence (no transfusions for 1 week prior to each assessment). No duration of these findings is required for confirmation of this response. A CR with incomplete blood count recovery (CRi) is defined as \<5% BM blasts with the ANC count \< 1 x 10\^9/L and/or the platelet count may be \< 100 x 10\^9/L. Where the date of the hematology assessment used is the earliest on or following the date of the BM sample up to 8 days after the BM date.

    Time frame: Day 1 (randomization) to 40 months

  5. Duration of Remission Assessed by the IRC Based on Kaplan-Meier Estimates

    The time from the date CR or CRi was first documented until the date of documented relapse from CR/CRi. Duration of remission was defined only for those participants who achieved a CR or CRi, as determined by the IRC. Participants who were lost to follow-up without documented relapse, or were alive at last follow-up without documented relapse were censored at the date of their last response assessment.

    Time frame: Day 1 (randomization) to 40 months; date of the first documented CR or CRi until date of first documented relapse.

  6. Number of Participants Who Achieved a Cytogenetic Complete Response (CRc-10) as Determined by the IRC.

    The CRc is a normal karyotype defined as no clonal abnormalities after review of at least 10 metaphases using conventional cytogenetic techniques. Cytogenetic complete remission rate (CRc) is when the following criteria are met: 1) CR criteria met and 2) an abnormal karyotype is present at baseline and 3) there is reversion to normal karyotype at the time of CR (based on ≥ 10 metaphases), where date of cytogenetic sample = date of BM sample used for the CR assessment

    Time frame: Day 1 (randomization) to 40 months

  7. Number of Participants With Adverse Events (AEs)

    AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death

    Time frame: Day 1 (randomization) up to last visit completed; final data cut off of 28 Feb 2017

  8. Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

    Time frame: Baseline to Cycle 3; at approximately 3 months

  9. Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

    Time frame: Baseline to Cycle 5, at approximately 5 months

  10. Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

    Time frame: Baseline to Cycle 7, at approximately 7 months

  11. Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

    Time frame: Baseline to Cycle 9, at approximately 9 months

  12. Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

    Time frame: Baseline to End of Study; at approximately 11-12 months

  13. HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

    Time frame: Baseline to Cycle 3, at approximately 3 months

  14. HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

    Time frame: Baseline to Cycle 5, at approximately 5 months

  15. HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

    Time frame: Baseline to Cycle 7, at approximately 7 months

  16. HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

    Time frame: Baseline to Cycle 9, at approximately 9 months

  17. HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

    Time frame: Baseline to end of study, at approximately 11-12 months

  18. HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Baseline to Cycle 3, at approximately 3 months

  19. HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Baseline to Cycle 5, at approximately 5 months

  20. HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Baseline to Cycle 7, at approximately 7 months

  21. HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Baseline to Cycle 9, at approximately 9 months

  22. HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Baseline to end of study, at approximately 11-12 months

  23. HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

    Time frame: Baseline to Cycle 3, at approximately 3 months

  24. HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

    Time frame: Baseline to Cycle 5, at approximately 5 months

  25. HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

    Time frame: Baseline to Cycle 7, at approximately 7 months

  26. HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

    Time frame: Baseline to Cycle 9, at approximately 9 months

  27. HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

    Time frame: Baseline to end of study, at approximately 11-12 months

  28. Healthcare Resource Utilization (HRU): Number of Inpatient Hospitalizations

    HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective.

    Time frame: Day 1 (randomization) to 40 months

  29. Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year

    HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.

    Time frame: Day 1 (randomization) to 40 months

  30. HRU: Number of Participants Receiving Transfusions

    Count of study participants who had transfusions during the treatment phase. HRU is defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective.

    Time frame: Day 1 (randomization) to 40 months

  31. HRU: Rate of Transfusions Per Patient Year

    HRU is defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of transfusions per patient year was calculated as the total number of transfusions divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.

    Time frame: Day 1 (randomization) to 40 months

  32. Number of Participants in the Extension Phase With Treatment Emergent Adverse Events (TEAEs)

    AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death

    Time frame: From the date of informed consent for the Extension Phase through to the date of last dose of study drug + 28 days up to last visit completed 24 July 2016; maximum duration of exposure to Azacitidine was 871 days

07

Results

Posted Feb 26, 2015

Participant flow

This was a multicenter, international Phase 3 study conducted at 107 investigational sites in 18 countries including South Korea, China, Taiwan, Australia, Canada, United States, Poland, Russia, Czech Republic, Israel, France, Italy, Spain, Germany, United Kingdom, Belgium, Austria and the Netherlands.

Treatment Phase
Participant flow — Treatment Phase
MilestoneAzacitidine (AZA)Conventional Care Regimens (CCR)
Started241247
Treated population236240
Safety population236235
Evaluable population179191
Completed2413
Not completed217234
Withdrew: Adverse event8966
Withdrew: Disease progression1621
Withdrew: Withdrawal by subject2748
Withdrew: Death5358
Withdrew: Lost to follow-up01
Withdrew: Protocol violation01
Withdrew: Miscellaneous3239
Survival Follow-Up Phase
Participant flow — Survival Follow-Up Phase
MilestoneAzacitidine (AZA)Conventional Care Regimens (CCR)
Started140163
Completed1627
Not completed124136
Withdrew: Withdrawal by subject58
Withdrew: Lost to follow-up21
Withdrew: Death116124
Withdrew: Alive at study closure13
Extension Phase
Participant flow — Extension Phase
MilestoneAzacitidine (AZA)Conventional Care Regimens (CCR)
Started220
Safety population220
Completed00
Not completed220
Withdrew: Physician decision10
Withdrew: Adverse event50
Withdrew: Disease progression90
Withdrew: Withdrawal by subject20
Withdrew: Death50

Outcome measures

PrimaryKaplan-Meier Estimates for Overall Survival

Overall Survival was defined as the time from randomization to death from any cause. Overall survival was calculated by the formula: date of death - date of randomization + 1. Participants surviving at the end of the follow-up period or who withdrew consent to follow-up were censored at the date of last contact. Participants who were lost to follow-up were censored at the date last known alive.

Time frame:
Day 1 (randomization) to 40 months
Reported as:
Median · months
Kaplan-Meier Estimates for Overall Survival
monthsAzacitidine (AZA)Conventional Care Regimens (CCR)
Kaplan-Meier Estimates for Overall Survival10.4 (8.0 to 12.7)6.5 (5.0 to 8.6)
Statistical analysis
  • Azacitidine (AZA) vs Conventional Care Regimens (CCR) · Log Rank · p = 0.0829 · Hazard ratio (hr): 0.84 · 95% CI 0.69 to 1.02The hazard ratio is from a Cox proportional hazards model stratified by ECOG performance status and cytogenetic risk status.
  • Azacitidine (AZA) vs Conventional Care Regimens (CCR) · Log Rank · p = 0.1009 · Hazard ratio (hr): 0.85 · 95% CI 0.69 to 1.03The hazard ratio is from a Cox proportional hazards model stratified by ECOG performance status and cytogenetic risk status.
SecondaryOne-year Overall Survival Rate

Kaplan Meier methods were used to estimate the 1-year survival probabilities for time to death from any cause. Estimates of the 1-year (365 day) survival probabilities and corresponding 95% confidence intervals (CI) were presented by treatment group. The CI for the difference in the 1-year survival probabilities was derived using Greenwoods variance estimate.

Time frame:
From Day 1 (randomization) to 40 months
Reported as:
Number · percentage of participants
One-year Overall Survival Rate
percentage of participantsAzacitidine (AZA)Conventional Care Regimen
One-year Overall Survival Rate46.5 (40.1 to 52.7)34.3 (28.3 to 40.3)
Statistical analysis
  • Azacitidine (AZA) vs Conventional Care Regimen · Difference: 12.26 · 95% CI 3.5 to 21.0Estimates of the 1-year (365 day) survival probabilities and corresponding 95% confidence intervals (CI) were presented by treatment group. The CI for the difference in the 1-year survival probabilities was derived using Greenwoods variance estimate.
SecondaryEvent-free Survival (EFS)

Event-free survival was defined as the interval from the date of randomization to the date of treatment failure, progressive disease, relapse after complete remission (CR) or complete remission with incomplete blood count recovery (CRi), death from any cause, or lost to follow-up, whichever occurs first. Participants who were still alive without any of these events were censored at the date of their last response assessment.

Time frame:
Day 1 (randomization) to date of treatment failure, progressive disease, relapse after Complete Remission (CR) or Complete remission with incomplete blood count recovery (CRi), death from any cause. Day 1 (randomization) to 40 months
Reported as:
Median · months
Event-free Survival (EFS)
monthsAzacitidine (AZA)Conventional Care Regimens (CCR)
Event-free Survival (EFS)6.7 (5.0 to 8.8)4.8 (3.8 to 6.0)
Statistical analysis
  • Azacitidine (AZA) vs Conventional Care Regimens (CCR) · Log Rank · p = 0.1495 · Hazard ratio (hr): 0.87 · 95% CI 0.72 to 1.05The hazard ratio is from an unstratified Cox proportional hazards model.
SecondaryRelapse-Free Survival (RFS) for Participants Who Achieved a Complete Remission (CR) or Complete Remission With Incomplete Blood Count Recovery (CRi)

Relapse-free survival was defined as the interval from the date of first documented CR or CRi to the date of relapse, death from any cause, or lost to follow-up, whichever occurred first. Participants who were still alive and in continuous CR or CRi were censored at the date of their last response assessment.

Time frame:
Day 1 of first documented CR or CRi to the date of relapse, death from any cause, or lost to follow-up. Day 1 (randomization) to 40 months
Reported as:
Median · months
Relapse-Free Survival (RFS) for Participants Who Achieved a Complete Remission (CR) or Complete Remission With Incomplete Blood Count Recovery (CRi)
monthsAzacitidine (AZA)Conventional Care Regimen
Relapse-Free Survival (RFS) for Participants Who Achieved a Complete Remission (CR) or Complete Remission With Incomplete Blood Count Recovery (CRi)9.3 (6.7 to 12.4)10.5 (7.3 to 12.3)
Statistical analysis
  • Azacitidine (AZA) vs Conventional Care Regimen · Log Rank · p = 0.5832 · Hazard ratio (hr): 1.11 · 95% CI 0.75 to 1.66The hazard ratio is from an unstratified Cox proportional hazards model.
SecondaryPercentage of Participants Who Achieved a Morphologic CR + CRi as Determined by the Independent Review Committee (IRC) Based on International Working Group (IWG) Response Criteria for Acute Myeloid Leukemia (AML)

A complete remission (CR) is defined as a leukemia-free state defined as less than 5% blasts in a BM aspirate with marrow spicules and with at least 200 nucleated cells (there should be no blasts with Auer rods), an absolute neutrophil count (ANC) of ≥ 1 x 10\^9/L, a platelet count ≥ 100 x 10\^9/L, and transfusion independence (no transfusions for 1 week prior to each assessment). No duration of these findings is required for confirmation of this response. A CR with incomplete blood count recovery (CRi) is defined as \<5% BM blasts with the ANC count \< 1 x 10\^9/L and/or the platelet count may be \< 100 x 10\^9/L. Where the date of the hematology assessment used is the earliest on or following the date of the BM sample up to 8 days after the BM date.

Time frame:
Day 1 (randomization) to 40 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Morphologic CR + CRi as Determined by the Independent Review Committee (IRC) Based on International Working Group (IWG) Response Criteria for Acute Myeloid Leukemia (AML)
percentage of participantsAzacitidine (AZA)Conventional Care Regimens (CCR)
Percentage of Participants Who Achieved a Morphologic CR + CRi as Determined by the Independent Review Committee (IRC) Based on International Working Group (IWG) Response Criteria for Acute Myeloid Leukemia (AML)27.825.1
Statistical analysis
  • Azacitidine (AZA) vs Conventional Care Regimens (CCR) · Fisher Exact · p = 0.5384P-value is from Fishers exact test
SecondaryDuration of Remission Assessed by the IRC Based on Kaplan-Meier Estimates

The time from the date CR or CRi was first documented until the date of documented relapse from CR/CRi. Duration of remission was defined only for those participants who achieved a CR or CRi, as determined by the IRC. Participants who were lost to follow-up without documented relapse, or were alive at last follow-up without documented relapse were censored at the date of their last response assessment.

Time frame:
Day 1 (randomization) to 40 months; date of the first documented CR or CRi until date of first documented relapse.
Reported as:
Median · months
Duration of Remission Assessed by the IRC Based on Kaplan-Meier Estimates
monthsAzacitidine (AZA)Conventional Care Regimen
Duration of Remission Assessed by the IRC Based on Kaplan-Meier Estimates10.4 (7.2 to 15.2)12.3 (9.0 to 17.0)
SecondaryNumber of Participants Who Achieved a Cytogenetic Complete Response (CRc-10) as Determined by the IRC.

The CRc is a normal karyotype defined as no clonal abnormalities after review of at least 10 metaphases using conventional cytogenetic techniques. Cytogenetic complete remission rate (CRc) is when the following criteria are met: 1) CR criteria met and 2) an abnormal karyotype is present at baseline and 3) there is reversion to normal karyotype at the time of CR (based on ≥ 10 metaphases), where date of cytogenetic sample = date of BM sample used for the CR assessment

Time frame:
Day 1 (randomization) to 40 months
Reported as:
Number · participants
Number of Participants Who Achieved a Cytogenetic Complete Response (CRc-10) as Determined by the IRC.
participantsAzacitidine (AZA)Conventional Care Regimens (CCR)
Number of Participants Who Achieved a Cytogenetic Complete Response (CRc-10) as Determined by the IRC.515
Statistical analysis
  • Azacitidine (AZA) vs Conventional Care Regimens (CCR) · Fisher Exact · p = 0.0376P-value is from Fishers exact test
SecondaryNumber of Participants With Adverse Events (AEs)

AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death

Time frame:
Day 1 (randomization) up to last visit completed; final data cut off of 28 Feb 2017
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsAzacitidine (AZA)Conventional Care Regimen #3 Best Supportive Care OnlyConventional Care Regimen #2 Low-dose CytarabineConventional Care Regimen #1 Intensive Chemotherapy
At least one Treatment Emergent AE2343615342
At least one TEAE related to study drug188012439
Grade 3-4 adverse event2072614137
Grade 3-4 adverse event related to any study drug12509029
At least one Grade 5 (leading to death) TEAE5623389
Grade 5 adverse event related to any study drug120104
Serious TEAE1883011827
Serious TEAE related to any study drug8705614
TEAE leading to discontinuation of study drug11006811
Study drug-related TEAE leading to discontinuation220205
TEAE leading to study drug dose reduction8022
TEAE leading to study drug dose interruption1160614
TEAE causing study drug dose reduction/disruption13070
SecondaryHealth Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

Time frame:
Baseline to Cycle 3; at approximately 3 months
Reported as:
Mean · units on a scale
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimens (CCR)
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain-1.5 ± 24.69-1.9 ± 27.54
SecondaryHealth Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

Time frame:
Baseline to Cycle 5, at approximately 5 months
Reported as:
Mean · units on a scale
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimens (CCR)
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain-2.8 ± 27.36-7.1 ± 27.61
SecondaryHealth Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

Time frame:
Baseline to Cycle 7, at approximately 7 months
Reported as:
Mean · units on a scale
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimens (CCR)
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain-6.1 ± 26.90-12.2 ± 30.45
SecondaryHealth Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

Time frame:
Baseline to Cycle 9, at approximately 9 months
Reported as:
Mean · units on a scale
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimens (CCR)
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain-9.0 ± 27.90-10.2 ± 33.85
SecondaryHealth Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

Time frame:
Baseline to End of Study; at approximately 11-12 months
Reported as:
Mean · units on a scale
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimens (CCR)
Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain8.9 ± 33.546.1 ± 34.19
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

Time frame:
Baseline to Cycle 3, at approximately 3 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea5.1 ± 26.88-1.7 ± 30.69
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

Time frame:
Baseline to Cycle 5, at approximately 5 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea3.9 ± 27.49-6.6 ± 28.18
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

Time frame:
Baseline to Cycle 7, at approximately 7 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea0.4 ± 29.93-8.8 ± 28.61
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

Time frame:
Baseline to Cycle 9, at approximately 9 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea-4.9 ± 26.93-2.8 ± 26.87
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

Time frame:
Baseline to end of study, at approximately 11-12 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea12.6 ± 31.436.3 ± 35.22
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Baseline to Cycle 3, at approximately 3 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain-4.2 ± 17.98-0.3 ± 18.85
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Baseline to Cycle 5, at approximately 5 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain-4.4 ± 19.25-1.3 ± 20.41
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Baseline to Cycle 7, at approximately 7 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain1.6 ± 18.751.5 ± 23.08
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Baseline to Cycle 9, at approximately 9 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain3.5 ± 18.26-0.4 ± 22.81
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 PhysicalFunctioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Baseline to end of study, at approximately 11-12 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain-13.0 ± 26.74-9.4 ± 26.43
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

Time frame:
Baseline to Cycle 3, at approximately 3 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain0.9 ± 20.973.8 ± 26.42
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

Time frame:
Baseline to Cycle 5, at approximately 5 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain1.6 ± 22.509.0 ± 24.82
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

Time frame:
Baseline to Cycle 7, at approximately 7 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain5.1 ± 25.848.7 ± 27.91
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

Time frame:
Baseline to Cycle 9, at approximately 9 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain7.8 ± 27.2810.4 ± 23.09
SecondaryHRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

Time frame:
Baseline to end of study, at approximately 11-12 months
Reported as:
Mean · units on a scale
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain
units on a scaleAzacitidine (AZA)Conventional Care Regimen
HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain-4.4 ± 29.20-6.1 ± 27.90
SecondaryHealthcare Resource Utilization (HRU): Number of Inpatient Hospitalizations

HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective.

Time frame:
Day 1 (randomization) to 40 months
Reported as:
Number · participants
Healthcare Resource Utilization (HRU): Number of Inpatient Hospitalizations
participantsAzacitidine (AZA)Conventional Care Regimens (CCR)
Healthcare Resource Utilization (HRU): Number of Inpatient Hospitalizations139111
SecondaryHealthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year

HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.

Time frame:
Day 1 (randomization) to 40 months
Reported as:
Number · hospitalizations per patient year
Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year
hospitalizations per patient yearAzacitidine (AZA)Conventional Care Regimens (CCR)
Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year7.954.82
SecondaryHRU: Number of Participants Receiving Transfusions

Count of study participants who had transfusions during the treatment phase. HRU is defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective.

Time frame:
Day 1 (randomization) to 40 months
Reported as:
Number · participants
HRU: Number of Participants Receiving Transfusions
participantsAzacitidine (AZA)Conventional Care Regimen
HRU: Number of Participants Receiving Transfusions154134
Statistical analysis
  • Azacitidine (AZA) vs Conventional Care Regimen · negative binomial regression analysis · p = 0.0721 · Relative ratio: 0.79 · 95% CI 0.62 to 1.02
SecondaryHRU: Rate of Transfusions Per Patient Year

HRU is defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of transfusions per patient year was calculated as the total number of transfusions divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.

Time frame:
Day 1 (randomization) to 40 months
Reported as:
Number · transfusions per patient year
HRU: Rate of Transfusions Per Patient Year
transfusions per patient yearAzacitidine (AZA)Conventional Care Regimen
HRU: Rate of Transfusions Per Patient Year34.2336.04
SecondaryNumber of Participants in the Extension Phase With Treatment Emergent Adverse Events (TEAEs)

AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death

Time frame:
From the date of informed consent for the Extension Phase through to the date of last dose of study drug + 28 days up to last visit completed 24 July 2016; maximum duration of exposure to Azacitidine was 871 days
Reported as:
Number · participants
Number of Participants in the Extension Phase With Treatment Emergent Adverse Events (TEAEs)
participantsAzacitidine (AZA)
At least one Treatment Emergent AE20
At least one TEAE related to study drug13
At least one Grade 3-4 adverse event13
At least 1 Grade 3-4 TEAE related to study drug7
At least 1 Grade 5 TEAE4
At least 1 Grade 5 TEAE related to study drug0
At least 1 serious TEAE10
At least 1 serious TEAE related to study drug1
At least one serious Grade 3-4 TEAE8
TEAE leading to discontinuation of study drug3
Study drug-related TEAE leading to discontinuation1
TEAE leading to study drug dose reduction1
TEAE leading to study drug dose interruption only17
TEAE causing study dose reduction/interruption2

Adverse events

Collected over From first dose to 1) last dose + 28 days for azacitidine and low-dose cytarabine; 2) last dose + 70 days for intensive chemotherapy; 3) discontinuation for BSC only. Median duration was 191.5, 65.0, 125.0, 124.5 and 360.0 days for each group respectively. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azacitidine—188/236 (79.7%)226/236 (95.8%)
BSC Only—30/40 (75%)33/40 (82.5%)
Low-dose Cytarabine—118/153 (77.1%)151/153 (98.7%)
Intensive Chemotherapy—27/42 (64.3%)42/42 (100%)
Azacitidine-extension—10/22 (45.5%)18/22 (81.8%)
Most frequent serious events
Showing 10 of 258
Most frequent serious events
EventAzacitidineBSC OnlyLow-dose CytarabineIntensive ChemotherapyAzacitidine-extension
FEBRILE NEUTROPENIABlood and lymphatic system disorders59/23612/4038/1537/424/22
ACUTE MYELOID LEUKAEMIANeoplasms benign, malignant and unspecified (incl cysts and polyps)26/23612/4017/1530/421/22
PNEUMONIAInfections and infestations48/2363/4029/1533/422/22
PYREXIAGeneral disorders25/2363/4016/1532/420/22
CELLULITISInfections and infestations5/2364/403/1531/420/22
SEPTIC SHOCKInfections and infestations4/2361/404/1534/420/22
THROMBOCYTOPENIABlood and lymphatic system disorders6/2360/4014/1530/420/22
ANAEMIABlood and lymphatic system disorders10/2361/4011/1530/421/22
SEPSISInfections and infestations12/2361/409/1532/420/22
NEUTROPENIC SEPSISInfections and infestations7/2362/404/1531/420/22
Most frequent other events
Showing 10 of 93
Most frequent other events
EventAzacitidineBSC OnlyLow-dose CytarabineIntensive ChemotherapyAzacitidine-extension
NAUSEAGastrointestinal disorders93/2363/4043/15324/423/22
DIARRHOEAGastrointestinal disorders87/2365/4034/15321/425/22
PYREXIAGeneral disorders77/2367/4056/15321/424/22
CONSTIPATIONGastrointestinal disorders99/2369/4042/15316/421/22
HYPOKALAEMIAMetabolism and nutrition disorders54/2366/4045/15316/423/22
NEUTROPENIABlood and lymphatic system disorders69/2361/4043/15314/426/22
FEBRILE NEUTROPENIABlood and lymphatic system disorders28/2362/4021/15312/420/22
THROMBOCYTOPENIABlood and lymphatic system disorders60/2362/4037/1539/426/22
ASTHENIAGeneral disorders53/2368/4032/1535/426/22
DECREASED APPETITEMetabolism and nutrition disorders61/2368/4033/1537/422/22

Baseline characteristics

The intent-to-treat (ITT) population is defined as all participants who were randomized, independent of whether they received study treatment or not.

Age, Continuous
Age, Continuous(years)Azacitidine (AZA)Conventional Care Regimens (CCR)Total
Mean75.4 ± 5.6075.1 ± 5.5775.2 ± 5.58
Age, Customized
Age, Customized(participants)Azacitidine (AZA)Conventional Care Regimens (CCR)Total
<75 years103120223
≥75 years138127265
Sex: Female, Male
Sex: Female, Male(Participants)Azacitidine (AZA)Conventional Care Regimens (CCR)Total
Female10298200
Male139149288
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Azacitidine (AZA)Conventional Care Regimens (CCR)Total
0 = Fully Active5457111
1 = Restrictive but Ambulatory132132264
2 = Ambulatory but unable to work5558113
3 = Limited Self Care000
4 = Completely disabled000
World Health Organization Acute Myeloid Leukemia (AML) Classification
World Health Organization Acute Myeloid Leukemia (AML) Classification(participants)Azacitidine (AZA)Conventional Care Regimens (CCR)Total
AML with myelodysplasia-related changes7583158
Therapy-related myeloid neoplasms812158
AML with recurrent genetic abnormalities5914
AML not otherwise specified153143296
Bone Marrow-Blasts Counts
Bone Marrow-Blasts Counts(Percentage of Bone Marrow Blasts)Azacitidine (AZA)Conventional Care Regimens (CCR)Total
Mean66.6 ± 24.7170.2 ± 22.2868.5 ± 23.56
08

Study locations

112 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Peter MacCallum Cancer Centre
    East Melbourne, Victoria 3002, Australia
  • Western Hospital
    Footscray, Victoria 3011, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
  • St Vincent's Hospital
    Fitzroy, 3065, Australia
  • Klinikum Wels-Grieskirchen GmbH
    Wels, Upper Austria 4600, Austria
  • Wilhelminenspital, I Medizinische Abt.
    Wien, Vienna 1160, Austria
  • Landeskliniken Salzburg Saint Johanns-Spital, III Medizinische Abteilung
    Salzburg, 5020, Austria
  • Grand Hôpital de Charleroi
    Charleroi, Hainaut 6000, Belgium
  • Cliniques Universitaires UCL de Mont-Godinne
    Yvoir, Namur 5530, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, Oost-vlaanderen 9000, Belgium
  • Algemeen Ziekenhuis Sint-Jan
    Brugge, West-vlaanderen 8000, Belgium
  • Centre Hospitalier de Jolimont-Lobbes
    La Louvière, 7100, Belgium
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Cancer Care Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Ottawa Hospital General Campus
    Ottawa, Ontario K1H8L6, Canada
  • Sunnybrook Odette Cancer Centre
    Toronto, Ontario M4N 3M5, Canada
  • Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Centre Hospitalier de l'Université de Montréal pavilion Notre Dame
    Montreal, Quebec H2L 4M1, Canada
  • Hopital du Sacre Coeur de Montréal
    Montreal, Quebec H4J 1C5, Canada
  • Tom Baker Cancer Centre
    Calgary, T2N 2T9, Canada
  • Princess Margaret Hospital
    Ontario, M5G 2M9, Canada
  • The Third Hospital of Peking University
    Beijing, 100083, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Peoples Hospital of Jiangsu Province
    Jiangsu, 210029, China
  • Shanghai Ruijin Hospital
    Shanghai, 200025, China
  • Shanghai Changhai Hospital,the Second Military Medical University
    Shanghai, 200433, China
  • West China Hospital,Sichuan University
    Sichuan, 610041, China
  • Tianjin Blood Disease Hospital
    Tianjin, 3000200, China
  • Fakultni nemocnice Brno
    Brno, Jihormoravsky Kraj 625 00, Czechia
  • Fakultni nemocnice Olomouc, hemato-onkologicka klinika
    Olomouc, Olomoucký Kraj 775 20, Czechia
  • Vseobecna Fakultni Nemocnice v Praze
    Praha 2, Praha 128 08, Czechia
  • Ustav hematologie a krevni transfuze
    Praha 2, Praha 128 20, Czechia
  • Centre Hospitalier Régional Universitaire, Hôpital de Hautepierre
    Strasbourg, Alsace 67091, France
  • Hospital Avicenne, Service d'hematologie Clinique
    Bobigny, ILE-DE-France 93009, France
  • Hopital Percy Clamart
    Clamart Cedex, Ile-de-france 92141, France
  • Hôpital Saint Louis
    Paris Cedex 10, Ile-de-france 75475, France
  • Centre Hopitalier Universitaire Dupuytren
    Limoges, Limousin Lorraine 87042, France
  • Centre Hospitalier Universitaire de Toulouse
    Toulouse Cedex 09, Midi-pyrénées 31059, France
  • Centre Hospitalier Universitaire de Nice
    Nice Cedex 3, Nice 06202, France
  • CHRU d'Angers
    Angers cedex 09, Pays de La Loire 49933, France
  • Centre Hospitalier Universitaire Nantes, Hotel Dieu
    Nantes Cedex 1, Pays de La Loire 44093, France
  • Centre Hospitalier Universitaire d'Amiens, Groupe Hospitalier Sud
    Amiens Cedex 1, Picardie 80054, France
  • Hôpital de la Conception
    Marseille, Provence Alpes Cote D'azur 13385, France
  • Centre Hospitalier de la Cote Basque
    Aquitaine, 64109, France
  • Centre Hospitalier Universitaire de Lyon-Hôpital Edouard Herriot
    Lyon Cedex 03, 69437, France
  • Universitatsklinikum Heidelberg
    Heidelberg, Baden-wuerttemberg 69120, Germany
  • Universitätsklinikum Ulm
    Ulm, Baden-wuerttemberg 89081, Germany
  • University of Rostock, Div. of Haematology and Oncology
    Rostock, Mecklenburg-vorpommern 18057, Germany
  • Heinrich-Heine-Universität Düsseldorf
    Düesseldorf, Nordrhein-westfalen 40211, Germany
  • Universitatsklinikum Essen, Zentrum fur Tumorforschung und Tumortherapie
    Essen, Nordrhein-Westfallen 45122, Germany
  • Universitätsklinikum Leipzig
    Leipzig, Sachsen 04103, Germany
  • Universitätsklinikum Jena
    Jena, Thueringen 07747, Germany
  • Soroka Medical Center
    Beer Sheva, Beersheva 84101, Israel
  • Assaf Harofeh Medical Centre
    Beer Yaakov, 70300, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 91031, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Rabin Medical Center
    Petach Tikva, 49100, Israel
  • Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Chaim Sheba Medical Center - Tel Hashomer, Heart Institute
    Tel Hashomer, 52621, Israel
  • IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture
    Rionero in Vulture, Potenza 85028, Italy
  • Azienda Sanitaria Ospedaliera "San Luigi Gonzaga"
    Orbassano, Turin 10043, Italy
  • Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria
    Alessandria, 15121, Italy
  • Azienda Ospedaliera Universitaria - Ospedali Riuniti di Ancona
    Ancona, 60126, Italy
  • Azienda Ospedaliera Policlinico di Bari
    Bari, 70124, Italy
  • Azienda Ospedaliera Sant'Orsola Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliero-Universitaria Careggi
    Firenze, 50134, Italy
  • Azienda Ospedaliera Bianchi-Melacrino-Morelli
    Reggio Calabria, 89100, Italy
  • Azienda Policlinico Umberto I di Roma
    Roma, 00161, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine
    Udine, 33100, Italy
  • Ospedale di Circolo e Fondazione Macchi
    Varese, 21100, Italy
  • Samsung Medical Center
    Gangnam-gu, Seoul 135-710, Korea, Republic of
  • Seoul National University Hospital
    Jongno-gu, Seoul 110-774, Korea, Republic of
  • Yonsei University Health System
    Seodaemun-gu, Seoul 120-752, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 700-721, Korea, Republic of
  • Seoul Saint Mary's Hospital Seocho-gu
    Seoul, 137-701, Korea, Republic of
  • Asan Medical Center
    Seoul, 138-736, Korea, Republic of
  • Korea University Hospital at Guro
    Seoul, 152-703, Korea, Republic of
  • Universitair Medisch Centrum Groningen
    Groningen, 9700 RB, Netherlands
  • Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku
    Wroclaw, Dolnoslaskie 50-367, Poland
  • Dolnoslaskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku
    Wroclaw, Dolnoslaskie 53-439, Poland
  • Wojewodzki Szpital Specjalistczny im. Mikolaja Kopernika
    Lódz, Lodzkie 93-510, Poland
  • Instytut Hematologii i Transfuzjologii
    Warszawa, Mazowieckie 02-776, Poland
  • Samodzielny Publiczny SK im. A. Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach
    Katowice, Slaskie 40-032, Poland
  • Central City Hospital # 7
    Ekaterinburg, 620137, Russian Federation
  • City Clinical Hospital n.a. S. P. Botkin
    Moscow, 125284, Russian Federation
  • State Healthcare Institution "Nizhny Novgorod N.A. Semashko Regional Clinical Hospital"
    Nizhniy Novgorod, 603126, Russian Federation
  • Saint Petersburg State Academician I.P. Pavlov Medical University
    Saint Petersburg, 197089, Russian Federation
  • Saratov State Medical University
    Saratov, 410 028, Russian Federation
  • Hospital Central de Asturias
    Oviedo, Asturias 33006, Spain
  • Hospital Son Dureta
    Palma de Mallorca, Baleares 07014, Spain
  • Hospital Son Llàtzer
    Palma de Mallorca, Baleares 07198, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28009, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain

Showing the first 100 of 112 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Seymour JF, Dohner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Recher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer. 2017 Dec 14;17(1):852. doi: 10.1186/s12885-017-3803-6. PubMed 29241450 ↗
  • Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Recher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Dohner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18. PubMed 25987659 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Jan 2014, 43 months.

Results were first posted in Feb 2015, 1 year 1 month after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 43 months is close to that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2010
First posted
Feb 24, 2010
StartActual
Jun 1, 2010
Primary completionActual
Jan 22, 2014
CompletionActual
Jul 25, 2016
Results first posted
Feb 26, 2015
Last update
Aug 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01074047
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Feb 24, 2010
Start date
Jun 1, 2010
Primary completion
Jan 22, 2014
Completion
Jul 25, 2016
Results posted
Feb 26, 2015
Last update
Aug 29, 2017

Study contacts

C L Beach, PharmD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion